Showing results (211-220 of 412) with videos related to

Sort By:
Pageof 42
Clinical Lymphoma, Myeloma & Leukemia|July 20, 2019
High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With ChemoimmunotherapyBrady E Beltran, Sally Paredes, Denisse Castro, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Associated malignancies in patients with Waldenström's macroglobulinemia and their kinChristina Hanzis, Rohit P Ojha, Zachary Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 24, 2013
Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studiesJorge J Castillo, Randall R Ingham, John L Reagan, et al.
Leukemia & Lymphoma|June 21, 2021
Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and managementJorge J Castillo, Brady E Beltran, Luis Malpica, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|August 13, 2011
Peripheral T-cell lymphoma with a regulatory T-cell phenotype: report of a nodal and an extranodal case from PeruBrady E Beltran, Domingo Morales, Pilar Quinones, et al.
Leukemia & Lymphoma|November 29, 2012
Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotypePeter S Nakhla, James N Butera, Diana O Treaba, et al.
Case Reports in Hematology|September 7, 2012
Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the LiteratureDiana O Treaba, Salwa Khedr, Shamlal Mangray, et al.
Blood|December 25, 2013
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesisZachary R Hunter, Lian Xu, Guang Yang, et al.
Blood|March 14, 2014
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemiaMariateresa Fulciniti, Nicola Amodio, Rajya Lakshmi Bandi, et al.
American Journal of Hematology|April 10, 2014
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom MacroglobulinemiaIrene M Ghobrial, Thomas E Witzig, Morie Gertz, et al.
Pageof 42